Skip to main content
Contact Us
Subscribe
E-Edition
76°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MiNK Therapeutics, Inc. - Common Stock
(NQ:
INKT
)
64.17
+56.44 (+730.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 11, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MiNK Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Today 17:06 EDT
Via
Benzinga
What's going on in today's after hours session
Today 17:00 EDT
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Today 14:37 EDT
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Today 13:06 EDT
Via
Benzinga
A Look at MiNK Therapeutics's Upcoming Earnings Report
May 14, 2025
Via
Benzinga
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
Today 12:33 EDT
MiNK Therapeutics shares jumped as new clinical data show durable remission in testicular cancer and tumor reduction in gastric cancer using its iNKT cell therapy, agenT-797, in combination with...
Via
Benzinga
Dow Dips Over 200 Points; Levi Strauss Posts Upbeat Earnings
Today 10:41 EDT
Via
Benzinga
Topics
Stocks
MiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell Therapy
Today 10:21 EDT
“These findings are part of a growing body of clinical evidence supporting the potential of agenT-797 in solid tumors,” the company said.
Via
Stocktwits
12 Health Care Stocks Moving In Friday's Pre-Market Session
Today 8:07 EDT
Via
Benzinga
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
Today 7:30 EDT
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 10, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
June 02, 2025
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
May 15, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
May 05, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
March 18, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For May 15, 2025
May 15, 2025
Via
Benzinga
Earnings Scheduled For March 18, 2025
March 18, 2025
Via
Benzinga
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
March 04, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
February 24, 2025
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
February 20, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
February 12, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
Top movers analysis one hour before the close of the markets on 2025-02-04: top gainers and losers in today's session.
February 04, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 29, 2025
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
January 28, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via
Chartmill
These stocks are moving in today's session
January 28, 2025
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
The market is filled with gapping stocks in Tuesday's session.
January 28, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
January 23, 2025
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
December 18, 2024
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
November 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For November 14, 2024
November 14, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.
